Scholar Rock Holding Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on April 28, 2025, reports a significant management transition at Scholar Rock Holding Corp. effective April 27, 2025. The filing details the appointment of a new Chief Executive Officer (CEO) and other senior executives, alongside the departure of the former CEO and President, Dr. Jay T. Backstrom.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- CEO Transition: Dr. Jay T. Backstrom stepped down as CEO and President to become a Senior Advisor through October 31, 2025. He also resigned from the Board of Directors, reducing the Board size from ten to nine members.
- New CEO: David Hallal, previously Chairman of the Board, was appointed CEO and will remain Chairman.
- New Executive Team:
- Akshay Vaishnaw appointed President of Research & Development (R&D).
- R. Keith Woods appointed Chief Operating Officer (COO).
- Vikas Sinha appointed Chief Financial Officer (CFO), Principal Financial Officer, and Principal Accounting Officer.
- Board Committee Changes: Adjustments were made to the Nominating, Compensation, and Science, Innovation and Technology committees to reflect the new executive roles and Board composition.
Compensation and Employment Terms
The filing outlines substantial compensation packages for the new leadership team, effective April 27, 2025:
- David Hallal (CEO):
- Base Salary: $975,000 annually.
- Sign-on Bonus: $2 million.
- Annual Cash Bonus Target: 80% of base salary.
- Equity: Stock options with a grant date fair value of $7.5 million; 250,000 RSUs; and 500,000 target PSUs (max 250% achievement).
- Severance: 18 months of salary + bonus upon termination without cause; 2x salary + bonus upon change in control.
- Other Executives (Vaishnaw, Woods, Sinha):
- Base Salary: $800,000 annually each.
- Sign-on Bonus: $2 million for Dr. Vaishnaw; none specified for Woods and Sinha in this summary.
- Annual Cash Bonus Target: 60% of base salary.
- Equity: Stock options with a grant date fair value of $3 million each; 100,000 RSUs each; and 200,000 target PSUs each (max 250% achievement).
- Severance: 12 months of salary + bonus upon termination without cause; 1.5x salary + bonus upon change in control.
- Dr. Backstrom (Outgoing CEO): Will receive current base salary and benefits through the transition period (Oct 31, 2025). Post-employment benefits include 12 months of base salary, prorated bonus, 12 months of health benefits, and acceleration of certain equity awards.
Risks and Contingencies
The filing states that Dr. Backstrom's resignation is not the result of any disagreement with the Company regarding operations, policies, or practices. The Company expects to enter into a Transitional Services Agreement with Dr. Backstrom, the terms of which are subject to finalization.
Investor Verification Checklist
- Verify the impact of the leadership change on the Company's clinical development pipeline and strategic direction.
- Review the full employment agreements (Hallal Agreement and Executive Agreements) to be filed in the Q2 2025 Form 10-Q for detailed vesting schedules and performance metrics.
- Monitor the upcoming Annual Meeting of Stockholders on May 22, 2025, where Dr. Backstrom will not stand for re-election.
- Assess the financial impact of the new executive compensation packages, including the $2 million sign-on bonuses and equity grants, on future cash burn and dilution.